We investigated CSF concentrations of nitrite and nitrate as indicators of nitric oxide (NO) production in patients with tetrahydrobiopterin (BH 4 ) de®ciencies. Patients with 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase and dihydropteridine reductase de®ciencies exhibited decreased CSF nitrite + nitrate levels compared with healthy control subjects. Reduced levels of nitrite + nitrate were not in¯uenced by oral administration of 2.5±5.0 mg/kg tetrahydrobiopterin. Our data indicate impaired NO synthase function in patients with BH 4 de®ciency and suggest possible involvement in the neuronal cell dysfunction. Keywords: dihydropteridine, neurotoxicity, nitric oxide synthase, peroxynitrite, 6-pyruvoyl-tetrahydropterin, sepiapterin. ) and NO · radical, may cause oxidative neuronal cell damage and thus contribute to the neurological symptoms. The hph-1 mouse, a mutant with reduced BH 4 levels and low NOS activity in the brain, suggests that a de®ciency of BH 4 may become a limiting factor for NO production (Brand et al. 1996) . To further study the role of BH 4 in NO production and possible neuronal cell dysfunction, we measured the stable NO metabolites nitrite and nitrate in the CSF of patients with different variants of BH 4 de®ciency and found decreased levels compared to controls.
Tetrahydrobiopterin (BH 4 ) is the essential co-factor for aromatic amino acid hydroxylases and for the NO synthases (NOS; Tho Èny et al. 2000) . Classical BH 4 de®ciencies are caused by mutations in one of the genes coding for enzymes involved in BH 4 biosynthesis or regeneration (Blau et al. 2001b) . They are all characterized by severe monoamine neurotransmitters de®ciency, mostly accompanied by hyperphenylalaninemia. Typical clinical symptoms usually include neurological disturbances, muscle tone and co-ordination abnormalities, seizures, hypersalivation and delayed motor development. Recently it has been shown that the BH 4 metabolites dihydrobiopterin and sepiapterin competitively inhibit NOS (Jones et al. 2001) and that with low BH 4 concentrations the NOS reaction becomes uncoupled (Cosentino et al. 1998) . Under these conditions highly reactive peroxynitrite (ONOO ) ), generated from superoxide (O 2
)
) and NO · radical, may cause oxidative neuronal cell damage and thus contribute to the neurological symptoms. The hph-1 mouse, a mutant with reduced BH 4 levels and low NOS activity in the brain, suggests that a de®ciency of BH 4 may become a limiting factor for NO production (Brand et al. 1996) . To further study the role of BH 4 in NO production and possible neuronal cell dysfunction, we measured the stable NO metabolites nitrite and nitrate in the CSF of patients with different variants of BH 4 de®ciency and found decreased levels compared to controls.
Materials and methods

Patients and control subjects
Cerebrospinal¯uid (CSF) samples were obtained from 22 patients (aged 1±25 years) and 20 controls (aged 5 months to 14 years). Twelve patients had 6-pyruvoyl-tetrahydropterin synthase (PTPS) de®ciency, nine patients had dihydropteridine reductase (DHPR) de®ciency, and one patient had sepiapterin reductase (SR) de®ciency. Two patients with PTPS de®ciency were untreated and 10 were receiving standard treatment with L-Dopa/Carbidopa (3.0±12.0 mg/kg/day), 5-hydroxytryptophan (2.0±8.0 mg/kg/day), and BH 4 (2.5±5.0 mg/kg/day). All patients with DHPR de®ciency were on low-phenylalanine diets and supplemental L-Dopa/Carbidopa (3.5±10.0 mg/kg/day), 5-hydroxytryptophan (2.0±7.0 mg/ kg/day), and folinic acid (10±20 mg/day). The patient with SR de®ciency was receiving L-Dopa/Carbidopa (0.6 mg/kg/day), the MAO inhibitor ÔSelegilineÕ (0.08 mg/kg/day), and folinic acid (7.5 mg/day). The biochemical data from all patients are tabulated in the BIODEF database (http://www.bh4.org/biodef1.html). No neurological abnormalities were detected in any of the controls. Patients in whom infection was apparent or suspected were excluded from this study.
CSF sampling
Lumbar punctures were performed in the morning, and the ®rst 0.5 mL of CSF was discarded or used for a cell count. The next 1±2 mL of CSF were collected in an EDTA tube and frozen at ) 80°C until analyzed. The procedures used were in accordance with the current revision of the Helsinki Declaration of 1975.
Nitrite and nitrate measurement
The NOS product NO is extremely reactive and undergoes a series of reactions. The ®nal products in vivo are nitrite (NO 2 ) ) and nitrate (NO 3 ) ).
We measured the sum of nitrite and nitrate Ônitrite + nitrateÕ (the index of total NO production) using a commercial Colorimetric Assay Kit (Cayman Chemical, Ann Arbor, MI, USA). Nitrate was converted to nitrite utilizing nitrate reductase and measured with the Griess reagent. Absorbance was read at 570/630 nm in a MicroELISA Autoreader MR 530 (Dynatech, Chantilly, VA, USA).
Statistical methods
One way ANOVA was used to compare the results between controls and groups with the different BH 4 disorders. Differences were considered signi®cant when p-values were < 0.05.
Results
Patients with BH 4 de®ciencies displayed signi®cantly lower levels of nitrite + nitrate in CSF when compared with healthy controls (Table 1 ).
The mean concentrations in patients with DHPR and PTPS de®ciency were 0.60 and 0.30 lmol/L, respectively, compared with 2.69 lmol/L in controls. Nitrite + nitrate was not detectable in the CSF from the patient with SR de®ciency. In patients with PTPS de®ciency displaying low CSF biopterin levels the nitrite + nitrate concentrations were lower than in patients with DHPR de®ciency, with high total biopterin and dihydrobiopterin levels, but these differences were not statistically signi®cant (Table 1 ). The two patients with PTPS de®ciency, who were not receiving any treatment, had nitrite + nitrate levels similar to those of the group with BH 4 treatment (data not shown). There were also no differences in the CSF nitrite + nitrate levels when BH 4 was administered, regardless of the daily amount of BH 4 given (data not shown).
Discussion
It has been well documented that BH 4 de®ciency states, as seen in patients with inherited disorders of BH 4 metabolism, contributes to cerebral monoamine neurotransmitters depletion (Blau et al. 2001b) .
Although, some patients with BH 4 de®ciency have good outcomes when diagnosed early and treated adequately, there are a number of patients who do not respond to different therapy protocols and who show severe neurodevelopmental retardation despite substitution treatment with BH 4 and the neurotransmitter precursors L-Dopa and 5-hydroxytryptophan (Dudesek et al. 2001) . One of the reasons for the poor outcome may be the fact that BH 4 is not only the essential co-factor for tyrosine and tryptophan hydroxylases, the rate limiting enzymes in the biosynthesis of catecholamines and serotonin, but is also required for all three isoforms of NOS (Tho Èny et al. 2000) . A mouse mutant for the GTP cyclohydrolase I (hph-1 mouse), the ®rst enzyme in the biosynthesis of BH 4 , displayed low BH 4 concentrations and low NOS activity in the brain (Brand et al. 1996) . Furthermore, Heales et al. (1999) demonstrated a link between BH 4 levels and nitrite + nitrate levels in CSF. It has been suggested that under BH 4 de®cient conditions, the NOS reaction becomes uncoupled and that reduced NO and increased superoxide production may contribute to neuronal cell pathology through peroxynitrite generation ( Fig. 1; Tiefenbacher 2001) . Although, peroxynitrite is rather unstable and could also degrade to nitrate, even a small amount of peroxynitrite may be neurotoxic. Recently, it has been shown that some biopterin metabolites, e.g. dihydrobiopterin and sepiapterin, inhibit NOS in vitro (Jones et al. 2001) . These metabolites accumulate in the CSF of patients with DHPR and SR de®ciency (Hyland and Heales 1993; Bonafe Â et al. 2001) .
In this study, we documented that patients with BH 4 de®ciencies characterized by a de®ciency of monoamine neurotransmitters exhibited decreased NO production in the brain as measured by the concentration of nitrite and nitrate in the CSF. The decrease of the CSF nitrite + nitrate levels was similar in different variants of BH 4 de®ciency (e.g. PTPS, DHPR and SR de®ciency). While in patients with PTPS de®ciency reduced NO production may be explained by the low cerebral BH 4 concentrations, in patients with DHPR and SR de®ciency dihydrobiopterin probably potentates the effect of low BH 4 concentrations by inhibiting NOS (Fig. 1) . We recently proposed that sepiapterin, a metabolite which accumulates in patients with SR de®ciency, exhibits similar effects (Blau et al. 2001a) . We also showed that the oral administration of low doses of BH 4 (2±5 mg/kg/day) did not alter NO production in the brain. Thus, high dosage BH 4 therapy (10±20 mg/kg/day) and vitamins C and E supplementation may be necessary to improve *Total biopterin (biopterin + dihydrobiopterin + tetrahydrobiopterin). ** > 70% as dihydrobiopterin and biopterin (< 30% tetrahydrobiopterin). ***p < 0.005. ****p < 0.0005. neuronal NOS function and to prevent superoxide and peroxynitrite generation. In the hph-1 mouse subcutaneous administration of BH 4 (100 lmol/kg) plus ascorbate (1%, w/v) normalized brain NO metabolism ).
In conclusion, low CSF nitrite + nitrate levels in patients with different forms of BH 4 de®ciency have been demonstrated. We would suggest that low BH 4 and high dihydrobiopterin and sepiapterin concentrations in CSF may contribute to the pathophysiology of neurotransmitter de®ciency by uncoupling the NOS reaction.
